Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bosentan in Non Arteritic Ischemic Optic Neuropathy
NCT02377271Phase 3Recruiting
- Sponsor
- CHU Grenoble Alpes
- Start
- Aug 2015
- Primary completion
- Dec 2023
- Modality
- Nucleic Acid-Directed Small Molecules, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in non-arteritic anterior ischemic optic neuropathy (NAION) comparing Bosentan with Placebo (2 arms). Primary endpoint: Mean deviation of automated visual field at 3 months. Started Aug 2015; status: recruiting.
02
Drugs
bosentan
03
Conditions
non-arteritic anterior ischemic optic neuropathy (NAION)
Beyond the preview
Go deeper on NCT02377271.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02377271.